



## Clinical trial results:

### A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy

#### Summary

|                          |                  |
|--------------------------|------------------|
| EudraCT number           | 2008-007762-39   |
| Trial protocol           | DE               |
| Global end of trial date | 17 December 2010 |

#### Results information

|                                |               |
|--------------------------------|---------------|
| Result version number          | v1            |
| This version publication date  | 31 March 2017 |
| First version publication date | 31 March 2017 |

#### Trial information

##### Trial identification

|                       |              |
|-----------------------|--------------|
| Sponsor protocol code | IL1T-GA-0816 |
|-----------------------|--------------|

##### Additional study identifiers

|                                    |                         |
|------------------------------------|-------------------------|
| ISRCTN number                      | -                       |
| ClinicalTrials.gov id (NCT number) | NCT00958438             |
| WHO universal trial number (UTN)   | -                       |
| Other trial identifiers            | Study Name: PRE-SURGE 2 |

Notes:

#### Sponsors

|                              |   |
|------------------------------|---|
| Sponsor organisation name    | Regeneron Pharmaceuticals, Inc.   |
| Sponsor organisation address | 777 Old Saw Mill River Rd., Tarrytown, United States, 10591                                   |
| Public contact               | Clinical Trials information, Regeneron Pharmaceuticals, Inc.,<br>clinicaltrials@regeneron.com |
| Scientific contact           | Clinical Trials information, Regeneron Pharmaceuticals, Inc.,<br>clinicaltrials@regeneron.com |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |                  |
|--|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 17 December 2010 |
| Is this the analysis of the primary completion data? | No               |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 17 December 2010 |
| Was the trial ended prematurely?                     | No               |

Notes:

## General information about the trial

Main objective of the trial:

To determine the efficacy of 160 mg and 80 mg of weekly subcutaneous (SC) Rilonacept therapy compared to placebo in the prophylaxis of flares in subjects with intercritical gout initiating therapy with allopurinol.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Conference on Harmonisation (ICH) guidelines for Good Clinical Practice (GCP) and applicable regulatory requirements.

Background therapy:

Subjects received a daily dose of allopurinol 300 mg from Day 1 to the end of the follow-up period. Dose was increased, if needed, every 2 weeks in 100 mg increments to a maximum dose of 800 mg per day until the target serum uric acid level (<6.0 mg/dL) was achieved.

Evidence for comparator: -

|   |               |
|---|---------------|
| Actual start date of recruitment                          | 07 March 2009 |
| Long term follow-up planned                               | No            |
| Independent data monitoring committee (IDMC) involvement? | No            |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                   |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | Germany: 25       |
| Country: Number of subjects enrolled | India: 13         |
| Country: Number of subjects enrolled | Indonesia: 12     |
| Country: Number of subjects enrolled | South Africa: 186 |
| Country: Number of subjects enrolled | Taiwan: 12        |
| Worldwide total number of subjects   | 248               |
| EEA total number of subjects         | 25                |

Notes:

### Subjects enrolled per age group

|   |   |
|---|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23 months)  | 0 |

|                           |     |
|---------------------------|-----|
| Children (2-11 years)     | 0   |
| Adolescents (12-17 years) | 0   |
| Adults (18-64 years)      | 213 |
| From 65 to 84 years       | 35  |
| 85 years and over         | 0   |

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at 57 study sites in European Union (EU) and rest of the world between 7 March 2009 and 17 December 2010. A total of 471 subjects were screened in the study.

### Pre-assignment

Screening details:

Out of 471 subjects, 248 were randomized and treated in the study. Subjects were randomized in 1:1:1 ratio to receive Placebo or Rilonacept 80 mg or Rilonacept 160 mg.

### Period 1

|                              |   |
|------------------------------|---|
| Period 1 title               | Overall Study (Overall period) (overall period) |
| Is this the baseline period? | Yes   |
| Allocation method            | Randomised - controlled                         |
| Blinding used                | Double blind                                    |
| Roles blinded                | Subject, Investigator, Carer, Assessor          |

### Arms

|                              |         |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes     |
| <b>Arm title</b>             | Placebo |

Arm description:

Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.

|  |                      |
|--|----------------------|
| Arm type                               | Placebo              |
| Investigational medicinal product name | Placebo              |
| Investigational medicinal product code |                      |
| Other name                             |                      |
| Pharmaceutical forms                   | Powder for injection |
| Routes of administration               | Subcutaneous use     |

Dosage and administration details:

Subcutaneous injection in left and right upper arm, the left and right abdomen, and the left and right thigh.

|                  |                  |
|------------------|------------------|
| <b>Arm title</b> | Rilonacept 80 mg |
|------------------|------------------|

Arm description:

Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.

|  |                      |
|--|----------------------|
| Arm type                               | Experimental         |
| Investigational medicinal product name | Rilonacept           |
| Investigational medicinal product code |                      |
| Other name                             |                      |
| Pharmaceutical forms                   | Powder for injection |
| Routes of administration               | Subcutaneous use     |

Dosage and administration details:

Subcutaneous injection in left and right upper arm, the left and right abdomen, and the left and right thigh.

|                  |                   |
|------------------|-------------------|
| <b>Arm title</b> | Rilonacept 160 mg |
|------------------|-------------------|

Arm description:

Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

|  |                      |
|--|----------------------|
| Investigational medicinal product name | Rilonacept           |
| Investigational medicinal product code |                      |
| Other name                             |                      |
| Pharmaceutical forms                   | Powder for injection |
| Routes of administration               | Subcutaneous use     |

Dosage and administration details:

Subcutaneous injection in left and right upper arm, the left and right abdomen, and the left and right thigh.

| <b>Number of subjects in period 1</b> | Placebo | Rilonacept 80 mg | Rilonacept 160 mg |
|---------------------------------------|---------|------------------|-------------------|
| Started                               | 82      | 82               | 84                |
| Completed                             | 72      | 72               | 78                |
| Not completed                         | 10      | 10               | 6                 |
| Consent withdrawn by subject          | 4       | 2                | 1                 |
| Physician decision                    | 1       | -                | 1                 |
| Adverse Event                         | -       | 3                | -                 |
| Other than specified                  | 2       | 3                | 2                 |
| Protocol deviation                    | 3       | 2                | 2                 |

## Baseline characteristics

### Reporting groups

|   |                   |
|---|-------------------|
| Reporting group title   | Placebo           |
| Reporting group description:  |                   |
| Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.                          |                   |
| Reporting group title   | Rilonacept 80 mg  |
| Reporting group description:  |                   |
| Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.   |                   |
| Reporting group title   | Rilonacept 160 mg |
| Reporting group description:  |                   |
| Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15. |                   |

| Reporting group values | Placebo | Rilonacept 80 mg | Rilonacept 160 mg |
|------------------------|---------|------------------|-------------------|
| Number of subjects     | 82      | 82               | 84                |
| Age categorical        |         |                  |                   |
| Units: Subjects        |         |                  |                   |

|                           |         |         |         |
|---------------------------|---------|---------|---------|
| Age continuous            |         |         |         |
| Units: years              |         |         |         |
| arithmetic mean           | 51.7    | 52.6    | 49      |
| standard deviation        | ± 12.87 | ± 11.47 | ± 11.77 |
| Gender categorical        |         |         |         |
| Units: Subjects           |         |         |         |
| Female                    | 5       | 5       | 7       |
| Male                      | 77      | 77      | 77      |
| Race                      |         |         |         |
| Units: Subjects           |         |         |         |
| Asian                     | 29      | 23      | 30      |
| Black or African American | 10      | 14      | 10      |
| White                     | 43      | 45      | 44      |
| Ethnicity                 |         |         |         |
| Units: Subjects           |         |         |         |
| Not Hispanic or Latino    | 82      | 82      | 84      |
| Hispanic or Latino        | 0       | 0       | 0       |

| Reporting group values | Total |  |  |
|------------------------|-------|--|--|
| Number of subjects     | 248   |  |  |
| Age categorical        |       |  |  |
| Units: Subjects        |       |  |  |

|                    |   |  |  |
|--------------------|---|--|--|
| Age continuous     |   |  |  |
| Units: years       |   |  |  |
| arithmetic mean    |   |  |  |
| standard deviation | - |  |  |

|                                       |     |  |  |
|---------------------------------------|-----|--|--|
| Gender categorical<br>Units: Subjects |     |  |  |
| Female                                | 17  |  |  |
| Male                                  | 231 |  |  |
| Race<br>Units: Subjects               |     |  |  |
| Asian                                 | 82  |  |  |
| Black or African American             | 34  |  |  |
| White                                 | 132 |  |  |
| Ethnicity<br>Units: Subjects          |     |  |  |
| Not Hispanic or Latino                | 248 |  |  |
| Hispanic or Latino                    | 0   |  |  |

## End points

### End points reporting groups

|   |                   |
|---|-------------------|
| Reporting group title   | Placebo           |
| Reporting group description:<br>Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.                          |                   |
| Reporting group title   | Rilonacept 80 mg  |
| Reporting group description:<br>Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.   |                   |
| Reporting group title   | Rilonacept 160 mg |
| Reporting group description:<br>Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15. |                   |

### Primary: Number of Gout Flares Per Subject Assessed From Day 1 to Day 113 (Week 16)

|  |   |
|--|---|
| End point title  | Number of Gout Flares Per Subject Assessed From Day 1 to Day 113 (Week 16) <sup>[1]</sup> |
| End point description:<br>Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic; had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain; and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flares per participant was reported for this endpoint. Full analysis set (FAS) that included all randomized subjects who received any study medication, and was based on the treatment allocated by the Interactive voice response system (IVRS) at randomization (as randomized). Here, number of subjects analyzed = subjects with available data for this endpoint. |   |
| End point type   | Primary   |
| End point timeframe:<br>Day 1 to Day 133 (Week 16)   |   |

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: As the endpoint is descriptive in nature, no statistical analysis is provided.

| End point values                     | Placebo         | Rilonacept 80 mg | Rilonacept 160 mg |  |
|--------------------------------------|-----------------|------------------|-------------------|--|
| Subject group type                   | Reporting group | Reporting group  | Reporting group   |  |
| Number of subjects analysed          | 82              | 82               | 83                |  |
| Units: Gout flares                   |                 |                  |                   |  |
| arithmetic mean (standard deviation) | 1.23 (± 1.57)   | 0.35 (± 0.67)    | 0.34 (± 0.86)     |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Modified Gout Flares per Subject From Day 1 to Day 113 (Week 16)



|   |  |
|---|--|
| End point title   | Number of Modified Gout Flares per Subject From Day 1 to Day 113 (Week 16) |
| End point description:<br>Modified Gout Flare was defined using modified definition of a gout flare as subject-reported articular pain typical of a gout attack that was deemed to require treatment with anti-inflammatory therapy. Number of modified gout flares per subject were reported for this endpoint. Analysis was performed on FAS population. Here, number of subjects analyzed= subjects with available data for this endpoint. |  |
| End point type  | Secondary  |
| End point timeframe:<br>Day 1 to Day 113 (Week 16)  |  |

| End point values                     | Placebo         | Rilonacept 80 mg | Rilonacept 160 mg |  |
|--------------------------------------|-----------------|------------------|-------------------|--|
| Subject group type                   | Reporting group | Reporting group  | Reporting group   |  |
| Number of subjects analysed          | 82              | 82               | 83                |  |
| Units: modified gout flares          |                 |                  |                   |  |
| arithmetic mean (standard deviation) | 1.51 (± 1.87)   | 0.62 (± 1.32)    | 0.48 (± 0.99)     |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects with at Least one Flare From Day 1 to Day 113 (Week 16)

|   |  |
|---|--|
| End point title   | Percentage of Subjects with at Least one Flare From Day 1 to Day 113 (Week 16) |
| End point description:<br>Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic; had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain; and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of subjects with at least one gout flare was reported in this endpoint. Analysis was performed on FAS population. |  |
| End point type  | Secondary  |
| End point timeframe:<br>Day 1 to Day 113 (Week 16)  |  |

| End point values                  | Placebo         | Rilonacept 80 mg | Rilonacept 160 mg |  |
|-----------------------------------|-----------------|------------------|-------------------|--|
| Subject group type                | Reporting group | Reporting group  | Reporting group   |  |
| Number of subjects analysed       | 82              | 82               | 84                |  |
| Units: Percentage of Participants |                 |                  |                   |  |
| number (not applicable)           | 56.1            | 25.6             | 20.5              |  |

### Statistical analyses

No statistical analyses for this end point

---

**Secondary: Percentage of Subjects With at Least two Flares From Day 1 to Day 113 (Week 16)**

---

|                 |   |
|-----------------|---|
| End point title | Percentage of Subjects With at Least two Flares From Day 1 to Day 113 (Week 16) |
|-----------------|---|

End point description:

Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic; had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain; and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Percentage of subjects with at least two gout flares was reported in this endpoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 to Day 113 (Week 16)

---

| End point values              | Placebo         | Rilonacept 80 mg | Rilonacept 160 mg |  |
|-------------------------------|-----------------|------------------|-------------------|--|
| Subject group type            | Reporting group | Reporting group  | Reporting group   |  |
| Number of subjects analysed   | 82              | 82               | 84                |  |
| Units: Percentage of Subjects |                 |                  |                   |  |
| number (not applicable)       | 32.9            | 8.5              | 6                 |  |

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Number of Gout Flare Days per Subject From Day 1 to Day 113 (Week 16)**

---

|                 |   |
|-----------------|---|
| End point title | Number of Gout Flare Days per Subject From Day 1 to Day 113 (Week 16) |
|-----------------|---|

End point description:

Gout flare was defined as acute articular pain typical of a gout attack that required treatment with an anti-inflammatory therapeutic; had at least 3 of the following 4 signs or symptoms: joint swelling, tenderness, redness, and pain; and with at least 1 of the following: rapid onset of pain, decreased range of motion, joint warmth or other symptoms similar to a prior gout flare. Number of gout flare days per subject was reported for this endpoint. Analysis was performed on FAS population. Here, number of subjects analyzed= subjects with available data for this endpoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 to Day 113 (Week 16)

---

| End point values                     | Placebo         | Rilonacept 80 mg | Rilonacept 160 mg |  |
|--------------------------------------|-----------------|------------------|-------------------|--|
| Subject group type                   | Reporting group | Reporting group  | Reporting group   |  |
| Number of subjects analysed          | 82              | 82               | 83                |  |
| Units: gout flare days               |                 |                  |                   |  |
| arithmetic mean (standard deviation) | 11.7 (± 21)     | 4.3 (± 17.13)    | 1.86 (± 5.8)      |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Gout Flare Days with the Subject's Pain Score of 5 or More (From Daily Diary) per Subject From Day 1 to Day 113 (Week 16)

|                 |   |
|-----------------|---|
| End point title | Number of Gout Flare Days with the Subject's Pain Score of 5 or More (From Daily Diary) per Subject From Day 1 to Day 113 (Week 16) |
|-----------------|---|

End point description:

Subjects were asked to complete a telephone diary by calling the IVRS daily beginning at the baseline visit (Day 1) through the follow-up visit (Day 141) and reported their general well-being, gout symptoms, and weekly study drug administrations. At the onset of pain from a gout flare, subjects were to answer additional diary questions regarding their gout flare and had to continue daily flare assessments until they reported the flare had ended. If a flare occurred just prior to the follow-up visit (Day 141), subjects were to continue completing the daily diary until the flare resolved. Gout flare pain was assessed on a scale from 0 to 10 (with 0=no pain and 10=severe pain) within the past 24 hours. Analysis was performed on FAS population. Here, number of subjects analyzed= subjects with available data for this endpoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 to Day 113 (Week 16)

| End point values                     | Placebo         | Rilonacept 80 mg | Rilonacept 160 mg |  |
|--------------------------------------|-----------------|------------------|-------------------|--|
| Subject group type                   | Reporting group | Reporting group  | Reporting group   |  |
| Number of subjects analysed          | 82              | 82               | 83                |  |
| Units: gout flare days               |                 |                  |                   |  |
| arithmetic mean (standard deviation) | 4.28 (± 7.67)   | 1.67 (± 8.43)    | 0.88 (± 2.66)     |  |

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 20) regardless of seriousness or relationship to investigational product.

Adverse event reporting additional description:

Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'on treatment period' (time from the administration of first dose of study drug up to 35 days after the last dose of study drug).

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 12.0 |
|--------------------|------|

### Reporting groups

|                       |         |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.

|                       |                  |
|-----------------------|------------------|
| Reporting group title | Rilonacept 80 mg |
|-----------------------|------------------|

Reporting group description:

Two subcutaneous injections of Rilonacept 80 mg (for a total of 160 mg) as a loading dose on Day 1, followed by a single 80 mg injection of Rilonacept qw from Week 1 to Week 15.

|                       |                   |
|-----------------------|-------------------|
| Reporting group title | Rilonacept 160 mg |
|-----------------------|-------------------|

Reporting group description:

Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.

| Serious adverse events  | Placebo        | Rilonacept 80 mg | Rilonacept 160 mg |
|---|----------------|------------------|-------------------|
| Total subjects affected by serious adverse events                   |                |                  |                   |
| subjects affected / exposed   | 4 / 82 (4.88%) | 5 / 82 (6.10%)   | 3 / 84 (3.57%)    |
| number of deaths (all causes)                                       | 0              | 0                | 0                 |
| number of deaths resulting from adverse events                      |                |                  |                   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                |                  |                   |
| Gastric cancer  |                |                  |                   |
| subjects affected / exposed   | 0 / 82 (0.00%) | 1 / 82 (1.22%)   | 0 / 84 (0.00%)    |
| occurrences causally related to treatment / all                     | 0 / 0          | 0 / 1            | 0 / 0             |
| deaths causally related to treatment / all                          | 0 / 0          | 0 / 0            | 0 / 0             |
| Injury, poisoning and procedural complications                      |                |                  |                   |
| Contusion   |                |                  |                   |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 82 (1.22%) | 0 / 82 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Fall  |                |                |                |
| subjects affected / exposed                     | 1 / 82 (1.22%) | 0 / 82 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Post procedural complication                    |                |                |                |
| subjects affected / exposed                     | 0 / 82 (0.00%) | 1 / 82 (1.22%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Road traffic accident                           |                |                |                |
| subjects affected / exposed                     | 1 / 82 (1.22%) | 0 / 82 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Tendon rupture                                  |                |                |                |
| subjects affected / exposed                     | 1 / 82 (1.22%) | 0 / 82 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Upper limb fracture                             |                |                |                |
| subjects affected / exposed                     | 1 / 82 (1.22%) | 0 / 82 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Vascular disorders                              |                |                |                |
| Haematoma                                       |                |                |                |
| subjects affected / exposed                     | 1 / 82 (1.22%) | 0 / 82 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Hypertension                                    |                |                |                |
| subjects affected / exposed                     | 1 / 82 (1.22%) | 0 / 82 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| Cardiac failure                                 |                |                |                |
| subjects affected / exposed                     | 0 / 82 (0.00%) | 0 / 82 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cor pulmonale                                   |                |                |                |
| subjects affected / exposed                     | 0 / 82 (0.00%) | 0 / 82 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                |                |                |
| Carpal tunnel syndrome                          |                |                |                |
| subjects affected / exposed                     | 0 / 82 (0.00%) | 1 / 82 (1.22%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Umbilical hernia, obstructive                   |                |                |                |
| subjects affected / exposed                     | 1 / 82 (1.22%) | 0 / 82 (0.00%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Skin and subcutaneous tissue disorders          |                |                |                |
| Ingrowing nail                                  |                |                |                |
| subjects affected / exposed                     | 0 / 82 (0.00%) | 0 / 82 (0.00%) | 1 / 84 (1.19%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Renal and urinary disorders                     |                |                |                |
| Nephrolithiasis                                 |                |                |                |
| subjects affected / exposed                     | 0 / 82 (0.00%) | 1 / 82 (1.22%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                |                |                |
| Appendicitis                                    |                |                |                |
| subjects affected / exposed                     | 0 / 82 (0.00%) | 1 / 82 (1.22%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pyelonephritis                                  |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 82 (0.00%) | 1 / 82 (1.22%) | 0 / 84 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | Placebo          | Rilonacept 80 mg | Rilonacept 160 mg |
|---|------------------|------------------|-------------------|
| Total subjects affected by non-serious adverse events |                  |                  |                   |
| subjects affected / exposed                           | 12 / 82 (14.63%) | 20 / 82 (24.39%) | 20 / 84 (23.81%)  |
| Injury, poisoning and procedural complications        |                  |                  |                   |
| Accidental overdose                                   |                  |                  |                   |
| subjects affected / exposed                           | 2 / 82 (2.44%)   | 6 / 82 (7.32%)   | 4 / 84 (4.76%)    |
| occurrences (all)                                     | 3                | 6                | 5                 |
| Nervous system disorders                              |                  |                  |                   |
| Headache  |                  |                  |                   |
| subjects affected / exposed                           | 2 / 82 (2.44%)   | 5 / 82 (6.10%)   | 1 / 84 (1.19%)    |
| occurrences (all)                                     | 2                | 6                | 1                 |
| General disorders and administration site conditions  |                  |                  |                   |
| Injection site erythema                               |                  |                  |                   |
| subjects affected / exposed                           | 0 / 82 (0.00%)   | 6 / 82 (7.32%)   | 7 / 84 (8.33%)    |
| occurrences (all)                                     | 0                | 21               | 20                |
| Infections and infestations                           |                  |                  |                   |
| Influenza   |                  |                  |                   |
| subjects affected / exposed                           | 6 / 82 (7.32%)   | 5 / 82 (6.10%)   | 5 / 84 (5.95%)    |
| occurrences (all)                                     | 6                | 5                | 5                 |
| Nasopharyngitis                                       |                  |                  |                   |
| subjects affected / exposed                           | 2 / 82 (2.44%)   | 3 / 82 (3.66%)   | 6 / 84 (7.14%)    |
| occurrences (all)                                     | 2                | 6                | 6                 |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date             | Amendment   |
|------------------|---|
| 14 January 2009  | <ul style="list-style-type: none"><li>- Removed the collection of blood samples for proteomics and RNA and information regarding analyses of such samples;</li><li>- Clarified requirement for collection of study drug injection volume by the subject;</li><li>- Indicated that this was a phase 3 trial;</li><li>- Made administrative clarifications and updates to the protocol.</li></ul>   |
| 14 October 2009  | <ul style="list-style-type: none"><li>- Specified that subjects with a purified protein derivative (PPD) tuberculin skin test of <math>\geq 10</math> mm in-duration were ineligible for the study;</li><li>- Specified that human immuno-deficiency virus (HIV) testing was required for sites in South Africa.</li><li>- Made miscellaneous administrative clarifications and updates to the protocol.</li></ul>  |
| 30 November 2009 | <ul style="list-style-type: none"><li>- Specified that subjects with a history of inadequate urate-lowering response to allopurinol, history of allergic reaction, contraindication, or intolerance to allopurinol, were ineligible for the study;</li><li>- Specified that subjects who had an absolute or relative contraindication to both naproxen and oral glucocorticoids (e.g., prednisolone, prednisone) were ineligible for the study;</li><li>- Specified stopping rules for discontinuation of study drug;</li><li>- Clarified that mandatory immediate termination from the study was required if a subject becomes pregnant during the study;</li><li>- Made administrative corrections to the protocol.</li></ul> |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported